| AEterna Zentaris: Uncovering Next Dominant Cancer Company The oncology-focused companies, led by Dendreon (DNDN) and Human Genome (HGSI), have become the biotechnology and drugs sectors' hottest new fad, stealing the spotlight and making once-average Joes trading in the $2 range into, now, Hollywood stock market Broadway stars. With their names forged in stone for us to forever gaze upon the opportunity that could been, many were left looking forward and wondering who will steal the limelight and win the Oscar for the sexiest investment for 2010. So without further ado, ladies and gentlemen, grab your drink, get your popcorn, and let’s get this show started. Stepping first onto the stage is a small company by the name of Keryx (KERX), who began to pick up steam, gaining well over 122% year-to-date, as investors began to realize the potential of its so called “flagship product” perifosine. It is currently being tested under two Phase 3 indications for multiple myeloma and advanced colorectal cancer, with both clinical trials due to be completed in the second half of 2011. Notice that the quotations in between the words flagship product, that’s not a mistake, in fact, that’s the main reason why AEterna Zentaris Inc. (AEZS) remains at the highly undervalued price per share of $1.25 versus Keryx’s $5.65.Complete Story » seekingalpha.com |
Five Key Factors Weighing on Dendreon Michael Becker submits:Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for Provenge® [sipuleucel-T], the first active immunotherapy approved for the treatment of cancer in the U.S. On Thursday, shares of Dendreon traded as low as $28.01, down more than 50% from their high, prompting us to briefly review some of the key factors weighing on the company at this time.Product pricing and reimbursementComplete Story » seekingalpha.com |
AACC Meeting Buzz Fuels Rally in Diagnostics Rod Raynovich submits:The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors. A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap players, and new product and technology news should help support the rally. As of mid a.m. trading on Monday, many diagnostic stocks were up 2% with the S&P up 0.9%.Here is a financial summary from last week's earnings announcements:Complete Story » seekingalpha.com |
Egg Probe Tracks Tainted Feed Early tests suggested chicken feed may have become contaminated after it arrived at the Iowa farm at the center of a huge egg recall, helping investigators zero in on the cause of this summer's salmonella outbreak. online.wsj.com |
China Analyst: 10 Pharma Stocks With Highest Growth Potential Douglas Cress submits:China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside. The companies on the list were selected by calculating the difference between the stocks’ current price and Wall Street analysts’ average target price. While the companies on the list are not China-based, they cover a wide array of therapeutic areas, from biodefense to stem cell therapy. Below, we provide more information on the companies selected by China Analyst. ARYx Therapeutics, Inc. (NASDAQ: ARYX) has the highest upside potential in its market: 984.7%, or an average target price of $4.25, according to China Analyst. ARYx develops drugs for large chronic-disease markets that are not adequately served by currently available therapies due to drug design or metabolic problems. ARYx takes drugs that are already on the market and searches for ways to improve their safety and efficacy. Its pipeline includes potential treatments for gastrointestinal disorders, atrial fibrillation, and psychiatric disorders.Complete Story » seekingalpha.com |